Top

Published in:

01-04-2010 | Epidemiology

P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case–control studies

Authors: Zhizhong Zhang, Meilin Wang, Dongmei Wu, Miaomiao Wang, Na Tong, Yuanyuan Tian, Zhengdong Zhang

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Abstract

P53 is a tumor suppressor gene and plays important roles in the etiology of breast cancer. Studies revealing conflicting results on the role of p53 codon 72 polymorphism (G>C) on breast cancer risk led us to perform a meta-analysis to investigate this relationship. Thirty-nine published studies, including 26,041 breast cancer cases and 29,679 controls were identified. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. The overall results suggested that the variant genotypes were associated with a significantly reduced breast cancer risk (GC vs. GG: OR = 0.91, 95% CI: 0.83–1.00; CC/GC vs. GG: OR = 0.90, 95% CI: 0.82–0.99). In the stratified analyses, significantly decreased risks were also found among European populations (GC vs. GG: OR = 0.89, 95% CI: 0.80–0.99; CC/GC vs. GG: OR = 0.88, 95% CI: 0.80–0.98) and studies with population-based controls (GC vs. GG: OR = 0.88, 95% CI: 0.78–0.98; CC/GC vs. GG: OR = 0.87, 95% CI: 0.78–0.97). The results suggested that p53 codon 72 polymorphism may contribute to susceptibility to breast cancer, especially in Europeans. Additional well-designed large studies were required to validate this association in different populations.

Available only for authorised users

Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156CrossRefPubMed

Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282CrossRefPubMed

Veronesi U, Boyle P, Goldhirsch A et al (2005) Breast cancer. Lancet 365:1727–1741CrossRefPubMed

Bartkova J, Lukas J, Strauss M et al (1995) Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775–778PubMed

Porter-Jordan K, Lippman ME (1994) Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 8:73–100PubMed

Callahan R, Cropp CS, Merlo GR et al (1992) Somatic mutations and human breast cancer. A status report. Cancer 69:1582–1588CrossRefPubMed

Hollstein M, Sidransky D, Vogelstein B et al (1991) p53 mutations in human cancers. Science 253:49–53CrossRefPubMed

Petitjean A, Achatz MI, Borresen-Dale AL et al (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157–2165CrossRefPubMed

Harris N, Brill E, Shohat O et al (1986) Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650–4656PubMed

10.

Dumont P, Leu JI, Della Pietra ACIII et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed

11.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed

12.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

13.

Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed

14.

Kawajiri K, Nakachi K, Imai K et al (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085–1089CrossRefPubMed

15.

Sjalander A, Birgander R, Hallmans G et al (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316CrossRefPubMed

16.

Weston A, Pan CF, Ksieski HB et al (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112PubMed

17.

Wang-Gohrke S, Rebbeck TR, Besenfelder W et al (1998) p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18:2095–2099PubMed

18.

Khaliq S, Hameed A, Khaliq T et al (2000) P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test 4:23–29CrossRefPubMed

19.

Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389–392CrossRefPubMed

20.

Li T, Lu ZM, Guo M et al (2002) p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95:2571–2576CrossRefPubMed

21.

Wang-Gohrke S, Becher H, Kreienberg R et al (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12:269–272CrossRefPubMed

22.

Buyru N, Tigli H, Dalay N (2003) P53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711–714PubMed

23.

Huang XE, Hamajima N, Katsuda N et al (2003) Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307–311CrossRefPubMed

24.

Mabrouk I, Baccouche S, El-Abed R et al (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 1010:764–770CrossRefPubMed

25.

Suspitsin EN, Buslov KG, Grigoriev MY et al (2003) Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103:431–433CrossRefPubMed

26.

Mahasneh AA, Abdel-Hafiz SS (2004) Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 25:1568–1573PubMed

27.

Noma C, Miyoshi Y, Taguchi T et al (2004) Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197–203CrossRefPubMed

28.

Kalemi TG, Lambropoulos AF, Gueorguiev M et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65CrossRefPubMed

29.

Ohayon T, Gershoni-Baruch R, Papa MZ et al (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92:1144–1148CrossRefPubMed

30.

Siddique MM, Balram C, Fiszer-Maliszewska L et al (2005) Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 14:2245–2252CrossRefPubMed

31.

Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103CrossRefPubMed

32.

Damin AP, Frazzon AP, Damin DC et al (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30:523–529CrossRefPubMed

33.

Ma H, Hu Z, Zhai X et al (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27:766–771CrossRefPubMed

34.

Baynes C, Healey CS, Pooley KA et al (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27CrossRefPubMed

35.

Buyru N, Altinisik J, Demokan S et al (2007) p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207–213CrossRefPubMed

36.

Cox DG, Deer D, Guo Q et al (2007) The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health studies. Cancer Causes Control 18:621–625CrossRefPubMed

37.

Franekova M, Zubor P, Stanclova A et al (2007) Association of p53 polymorphisms with breast cancer: a case–control study in Slovak population. Neoplasma 54:155–161PubMed

38.

Garcia-Closas M, Kristensen V, Langerod A et al (2007) Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 121:2532–2538CrossRefPubMed

39.

Gochhait S, Bukhari SI, Bairwa N et al (2007) Implication of BRCA2 -26G>A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res 9:R71CrossRefPubMed

40.

Johnson N, Fletcher O, Palles C et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16:1051–1057CrossRefPubMed

41.

Khadang B, Fattahi MJ, Talei A et al (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173:38–42CrossRefPubMed

42.

Pharoah PD, Tyrer J, Dunning AM et al (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3:e42CrossRefPubMed

43.

Samson M, Swaminathan R, Rama R et al (2007) Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India. Asian Pac J Cancer Prev 8:253–257PubMed

44.

Schmidt MK, Reincke S, Broeks A et al (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584–9590CrossRefPubMed

45.

Sprague BL, Trentham-Dietz A, Garcia-Closas M et al (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 28:1680–1686CrossRefPubMed

46.

Cavallone L, Arcand SL, Maugard C et al (2008) Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8:96CrossRefPubMed

47.

Costa S, Pinto D, Pereira D et al (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32CrossRefPubMed

48.

De Vecchi G, Verderio P, Pizzamiglio S et al (2008) The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev 32:140–143CrossRefPubMed

49.

Gaudet MM, Gammon MD, Bensen JT et al (2008) Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 108:93–99CrossRefPubMed

50.

Lum SS, Chua HW, Li H et al (2008) MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:754–761CrossRefPubMed

51.

Nordgard SH, Alnaes GI, Hihn B et al (2008) Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival. Int J Cancer 123:577–585CrossRefPubMed

52.

Singh V, Rastogi N, Mathur N et al (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48–57CrossRefPubMed

53.

Storey A, Thomas M, Kalita A et al (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393:229–234CrossRefPubMed

54.

Damin AP, Karam R, Zettler CG et al (2004) Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat 84:131–137CrossRefPubMed

55.

Akil N, Yasmeen A, Kassab A et al (2008) High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer 99:404–407CrossRefPubMed

Title: P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case–control studies
Authors: Zhizhong Zhang
Meilin Wang
Dongmei Wu
Miaomiao Wang
Na Tong
Yuanyuan Tian
Zhengdong Zhang
Publication date: 01-04-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0480-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor

Outcome of axillary staging in early breast cancer: a meta-analysis

A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding

Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines

Keynote webinar | Spotlight on antibody–drug conjugates in cancer